Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1405&sort=-funder_divisions
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-funder_divisions", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=-funder_divisions", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1406&sort=-funder_divisions", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1404&sort=-funder_divisions" }, "data": [ { "type": "Grant", "id": "9821", "attributes": { "award_id": "1R18HS028583-01A1", "title": "Evaluation of the SCALED (SCaling AcceptabLE cDs) Approach for the Implementation of Interoperable CDS for Venous Thromboembolism Prevention", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24555, "first_name": "Mario", "last_name": "Teran", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-08-05", "end_date": "2025-07-31", "award_amount": 985383, "principal_investigator": { "id": 25683, "first_name": "Genevieve B", "last_name": "Melton-Meaux", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 22989, "first_name": "Christopher J", "last_name": "Tignanelli", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 764, "ror": "https://ror.org/017zqws13", "name": "University of Minnesota", "address": "", "city": "", "state": "MN", "zip": "", "country": "United States", "approved": true }, "abstract": "ABSTRACT/PROJECT SUMMARY There is a global emphasis and critical need to close the patient-centered outcomes research (PCOR) evidence to practice gap. Forty percent of patients do not receive evidence-based practice, 20% receive unnecessary or potentially harmful care, and sadly, the list continues. We believe interoperable clinical decision support (CDS) is an indispensable solution to help close this gap; however, poor design, lack of interoperability, and implementation barriers hinder broad adoption. At the University of Minnesota, we have extensive experience implementing and scaling user-centered CDS systems, with over 20 use cases scaled each year. Importantly, we have developed and implemented both interoperable and federally-funded CDS systems. Our healthcare system leverages a rigorous approach, SCALED (SCaling AcceptabLE cDs), to guide CDS scaling across the system. But, the current climate of each healthcare system developing “home-grown” CDS for the exact same guidelines is not tenable. Building capabilities to rapidly translate PCOR to the bedside at scale and share interoperable CDS routinely with an updated knowledge base (living evidence synthesis) is necessary. Given this, we partnered with Apervita, developers of a healthcare technology platform for digital quality measurement and decision support, to develop an interoperable clinical practice guideline leveraging CPG-on-FHIR (Fast Healthcare Interoperability Resources) to prevent inpatient COVID-19 venous thromboembolism (VTE). The proposed R18 project will adapt a currently deployed CDS system to also deliver a VTE prevention guideline for adult patients with traumatic brain injury (TBI). We believe this is an ideal PCOR use case given PCORI’s continued effort to combat VTE in trauma and our experience previously implementing this guideline. Our overall goal is to successfully scale, evaluate, and maintain an interoperable TBI CDS across our 4-institution collaborative network. For Aim 1, we will conduct a Hybrid Type 2 randomized stepped wedge effectiveness- implementation trial to scale the CDS across 4 heterogeneous healthcare systems. Trial outcomes will be assessed using RE-AIM. Despite best efforts, it highly likely CDS adoption will vary across each site; Aim 2 will allow us to understand why. In Aim 2, we will evaluate implementation processes across trial sites guided by the EPIS implementation framework (determinant framework) using mixed-methods. Finally, it is critical that PCOR CPGs are maintained as evidence evolves. To date an accepted process for evidence maintenance does not exist. In Aim 3, we will pilot a “Living Guideline” process model for the VTE prevention CDS systems. Ultimately, this project will scale CDS across a diverse collaborative CDS community serving as an important demonstration of this critical healthcare challenge. We will integrate lessons learned for a planned national scaling in collaboration with engagement of U.S. trauma societies. Importantly, we will develop electronic health record (EHR)-specific IT playbooks for integration of interoperable CDS. Finally, we will pilot an approach for the “Living Guideline” and use that to sustain evidenced-based decision logic.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "9825", "attributes": { "award_id": "1I01HX003479-01A2", "title": "Disparities in Trust: COVID-19's Impact on Minority Veterans' Healthcare Experiences", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-08-01", "end_date": "2025-07-31", "award_amount": null, "principal_investigator": { "id": 25688, "first_name": "SUSAN L.", "last_name": "ZICKMUND", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1781, "ror": "https://ror.org/007fyq698", "name": "VA Salt Lake City Healthcare System", "address": "", "city": "", "state": "UT", "zip": "", "country": "United States", "approved": true }, "abstract": "Background: Patients’ trust in their healthcare system has a profound impact on their health and well-being and, as 1 of 4 overall key goals set by the Secretary of the Department of Veteran Affairs (VA), is a high priority for VA. Our previous research found lower levels of trust and higher perceived discrimination amongst Black and Latinx Veterans obtaining VA medical care compared to White Veterans. Considering the disproportionate impact of the pandemic on minority communities and the overlap between racial and digital divides, it is important to better understand the negative healthcare experiences of Black and Latinx Veterans in the aftermath of COVID-19. This information will be critical to improve care through targeted recommendations. Significance/Impact: Considering the disproportionate impact of COVID-19 on minority Veterans, the potential differential effects of a radically transformed healthcare environment, and the need to implement widespread vaccination and booster programs, our proposal focuses on an important VA priority. Our proposed research is highly responsive to the call to ensure the VA meets its strategic goal of inspiring Veterans to trust the healthcare system, as well as to HSR&D’s priority for actionable health equity research. VA also recognizes the importance of understanding the source of racial/ethnic disparities in trust with VA medical care in order to develop targeted recommendations to improve minority trust with VA health care. Innovativeness: The proposed Disparities In Care Experiences (DICE) study uses a novel mixed methods design that integrates the insights and richness of qualitative data collection with the precision of quantitative data analysis. DICE will be able to traverse from detection, to understanding, to forming the basis for interventions using Veterans’ own recommendations. Specific Aim 1. To examine the associations between Veterans’ race/ethnicity and their trust in the VA by conducting the DICE quantitative telephone survey with 1,050 Black, Latinx, and White male and female Veterans from 25 VA Medical Centers who used VA outpatient or telehealth services, or had care deferred. Specific Aim 2. To explore Veterans’ experiences contributing to trust in the VA by adding open -ended qualitative questions to the DICE quantitative telephone surveys for a subset of 150 male and female Veterans from our Aim 1 sample and to elicit actionable recommendations for improving Black and Latinx trust in VA. Specific Aim 3. Using the Aim 1 survey results and the Aim 2 Veteran recommendations, we will work with our operational partners and a key vendor to develop and disseminate a toolkit and training to empower VA stakeholders to improve the healthcare system to engender trust amongst Black and Latinx Veterans. Methodology: Using racial/ethnic stratification we will survey 1,050 Veterans at 25 VA medical centers on their experience of trust in VA. One hundred and fifty Veterans will also be asked open-ended questions about sources of trust/distrust across 12 domains of health care. We will use survey and qualitative methods to analyze the data from Aims 1 and 2, respectively. A toolkit development group will examine the Veteran recommendations and using a modified Delphi approach will create a toolkit designed to improve Black and Latinx Veterans’ trust in VA. Implementation/Next steps: We will partner with the Office of Health Equity, the Veteran Experience Office, the office of Analytics and Performance Integration, and vendor Dynamic Integration Services to ensure that the VA is thoroughly trained and responsive to the recommendations resulting from this work.", "keywords": [ "Acute", "Address", "Affect", "Area", "COVID-19", "COVID-19 disparity", "COVID-19 impact", "COVID-19 pandemic", "COVID-19 patient", "COVID-19 susceptibility", "Caring", "Categories", "Collaborations", "Continuity of Patient Care", "Data", "Data Analyses", "Data Collection", "Detection", "Development", "Economics", "Ensure", "Environment", "Ethnic Origin", "Ethnic group", "Face", "Female", "Frontline worker", "Future", "Goals", "Health", "Health Care Seeking Behavior", "Health Status", "Health care facility", "Health system", "Healthcare", "Healthcare Systems", "Individual", "Infection", "Intervention", "Latinx", "Light", "Measures", "Medical", "Medical center", "Methodology", "Methods", "Minority", "Minority Women", "Occupations", "Outcome", "Outpatients", "Patients", "Performance", "Personal Satisfaction", "Provider", "Qualitative Methods", "Race", "Racial Equity", "Recommendation", "Research", "Research Design", "SARS-CoV-2 infection", "Safety", "Sampling", "Services", "Source", "Stratification", "Suggestion", "Survey Methodology", "Surveys", "Technology", "Telemedicine", "Telephone", "Training", "Trust", "United States Department of Veterans Affairs", "Vaccination", "Vendor", "Veterans", "Veterans Health Administration", "Work", "care delivery", "comorbidity", "design", "digital", "disparity reduction", "distrust", "ethnic difference", "experience", "health care availability", "health care disparity", "health equity", "high risk", "implementation facilitation", "improved", "infection rate", "infection risk", "innovation", "insight", "male", "minority communities", "novel", "pandemic disease", "perceived discrimination", "pressure", "programs", "racial and ethnic", "racial and ethnic disparities", "racial difference", "racial disparity", "response", "satisfaction", "telehealth", "virtual healthcare" ], "approved": true } }, { "type": "Grant", "id": "9832", "attributes": { "award_id": "5I21RX003615-02", "title": "Exploring Barriers and Facilitators of Employment in Veterans with Opioid Use Disorders", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-05-01", "end_date": "2023-04-30", "award_amount": null, "principal_investigator": { "id": 24118, "first_name": "Mercy N", "last_name": "Mumba", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1699, "ror": "", "name": "TUSCALOOSA VETERANS AFFAIRS MEDICAL CTR", "address": "", "city": "", "state": "AL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1699, "ror": "", "name": "TUSCALOOSA VETERANS AFFAIRS MEDICAL CTR", "address": "", "city": "", "state": "AL", "zip": "", "country": "United States", "approved": true }, "abstract": "Significance: Living with an opioid use disorder (OUD) can make obtaining and sustaining employment a significant challenge. Adults who have a current OUD are significantly more likely to be unemployed and make less income compared to those with past OUD or those without lifetime OUD. For most individuals in treatment for an OUD, being employed is an important part of their recovery journey. Employment has several benefits, including reductions in preoccupation with symptoms, social isolation, risk of suicide, hopelessness, and economic instability, which often results in homelessness. However, with the advent of the COVID-19 pandemic, a significant number of Veterans have lost their jobs are currently seeking meaningful and competitive employment. Individual Placement and Support (IPS) is an evidenced-based supported employment intervention that is considered the gold standard of vocational rehabilitation. Only one small study has examined the effectiveness of IPS among individuals with OUD on methadone maintenance (n=45) and found that 50% of the IPS participants gained competitive employment compared to 5% of the waitlist control participants at 6 months (p<0.001). Prior to launching a well-warranted large-scale study of IPS for OUD, a better understanding of the barriers, facilitators, preferences, and employment accommodations in this unique patient population is needed to better tailor IPS delivery for Veterans recovering from OUD. Specific Aim: Examine the barriers and facilitators of sustained employment, including evaluation of employment challenges, occupational functioning, community integration, and quality of life and satisfaction among Veterans with OUD diagnosis. Methods and Procedures: This pilot study primarily utilizes a qualitative design, specifically phenomenology. Quantitative data will also be collected to better understand the patient population and will include (a) socio-demographic information such as age, level of education, employment history, income and source of income, housing and experiences with homelessness (b) history of substance use, (c) mental health- specifically depressive symptomology, (d) occupational functioning, and (e) quality of life related information. Utilizing phenomenology approach, qualitative interviews will be conducted with 50 Veterans, at least 6 of whom are or will be engaged in IPS services, 6 vocational rehabilitation specialists (includes 4 IPS specialists), 6 mental health or addiction recovery providers, and at least 6 employers/potential employers who may have or would be willing to employ persons with OUD. The participants must read and sign an IRB-approved informed consent prior to participating. To conduct the data analyses, the seven steps to procedural data analysis in phenomenological studies will be utilized. This approach examines participants associated meanings to the phenomenon under investigation and provides researchers the ability to identify the emerging themes. Primarily, an inductive thematic approach will be utilized as the primary method of data analysis. Conclusion: This SPiRE proposal addresses an area that lacks preliminary data, gathers new knowledge for an urgent need, informs the refinement of a tailored IPS intervention for OUD, allows an early career investigator to conduct a small study, allows a senior investigator to explore a new research area, leverages the investigators’ strengths and expertise, and advances the knowledge needed to promote successful recovery and reintegration into society for Veterans recovering from OUD, especially during and after the COVID-19 pandemic.", "keywords": [ "Address", "Adult", "Age", "Alabama", "Alcohols", "Area", "Attention", "COVID-19 pandemic", "COVID-19 pandemic effects", "Capital", "Cessation of life", "Client", "Communities", "Community Integration", "County", "Criminal Justice", "Data", "Data Analyses", "Deterioration", "Diagnosis", "Economic Burden", "Economic Recession", "Economics", "Educational Background", "Effectiveness", "Emotional", "Employment", "Employment Opportunities", "Employment Status", "Evaluation", "Feeling hopeless", "Geography", "Gold", "Health", "Health Care Costs", "Health Personnel", "Homelessness", "Hour", "Housing", "Income", "Individual", "Informed Consent", "Institutional Review Boards", "Intervention", "Interview", "Investigation", "Knowledge", "Left", "Measurable", "Medical", "Mental Depression", "Mental Health", "Methods", "Occupational", "Occupational Status", "Occupations", "Opioid", "Outcome", "Overdose", "Pain", "Participant", "Persons", "Pharmaceutical Preparations", "Pilot Projects", "Population", "Post-Traumatic Stress Disorders", "Poverty", "Predisposition", "Prevention", "Procedures", "Productivity", "Professional counselor", "Provider", "Public Health", "Quality of life", "Recommendation", "Recording of previous events", "Recovery", "Relapse", "Research", "Research Personnel", "Resources", "Services", "Social Well-Being", "Social isolation", "Societies", "Source", "Specialist", "Substance Use Disorder", "Suicide", "Supported Employment", "Symptoms", "Testing", "Unemployment", "Uninsured", "United States", "Veterans", "Vocational rehabilitation", "Waiting Lists", "Work", "addiction", "base", "career", "chronic painful condition", "community reintegration", "comorbidity", "cost", "depressive symptoms", "design", "disorder later incidence prevention", "evidence base", "experience", "experimental study", "health care availability", "health care service utilization", "improved", "methadone treatment", "middle age", "mortality", "opioid epidemic", "opioid overdose", "opioid use", "opioid use disorder", "pandemic disease", "patient oriented", "patient population", "phenomenological models", "preference", "prescription opioid", "professor", "programs", "rehabilitation service", "rural area", "satisfaction", "sociodemographics", "substance use", "substance use treatment", "suicidal risk", "treatment program" ], "approved": true } }, { "type": "Grant", "id": "9836", "attributes": { "award_id": "5U54CK000613-02", "title": "Infection Prevention and Antimicrobial Stewardship: Minding the Gaps: The Iowa Prevention Epicenter", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-06-01", "end_date": "2026-05-31", "award_amount": 1613024, "principal_investigator": { "id": 24153, "first_name": "Loreen A", "last_name": "Herwaldt", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 220, "ror": "https://ror.org/036jqmy94", "name": "University of Iowa", "address": "", "city": "", "state": "IA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 220, "ror": "https://ror.org/036jqmy94", "name": "University of Iowa", "address": "", "city": "", "state": "IA", "zip": "", "country": "United States", "approved": true }, "abstract": "We designed this proposal to address multiple CDC Epicenters' research priorities: preventing healthcare personnel (HCP) contamination, understanding and decreasing transmission of epidemiologically important pathogens including emerging respiratory viruses such as COVID-19, extending antimicrobial stewardship (AS), decreasing antimicrobial resistant infections, exploring sepsis epidemiology and prevention, quantifying and decreasing environmental contamination, implementing a decolonization program to obtain source control and decrease surgical site infections (SSI), applying innovative research methodology, and training the next generation of healthcare epidemiologists. Our proposed projects range from translational stage T0 to T2 and involve academic medical centers, a VA Medical Center, acute care hospitals, quick/urgent care centers (UCC), surgical patients, patients discharged from hospitals, and healthcare personnel (HCP) exposed to viral respiratory pathogens. Our long-term objectives are to: 1) improve the integration of infection prevention measures into HCP's patient care processes, 2) improve personal protective equipment (PPE) design and use to decrease HCP contamination and transmission, 3) improve surveillance for healthcare-associated infections (HAI), 4) identify practical ways to decrease spread of viral pathogens, 4) improve antibiotic use and decrease antimicrobial resistance, and 5) prevent hospital-onset sepsis (HOS) and HAI, including SSI. Core Project (CP) I uses methods from human factors engineering, ethnography, industrial hygiene, environmental microbiology, and computer visioning to improve PPE design, decrease HCP self-contamination, improve integration of PPE use and hand hygiene during patient care, and decrease bacterial and viral environmental contamination. CP II employs novel software via cellphones to expand surveillance for SSI and C. difficile infections after discharge and to monitor HCP exposed to respiratory viruses for signs or symptoms of infection. CP III and the Medium Optional Collaborative Project (OCP) address neglected opportunities for AS--UCC and patients at hospital discharge--by creating and testing novel AS metrics to decrease antibiotic prescriptions for acute respiratory tract infections in UCC (CP III) and by conducting a cluster-randomized trial of post-prescription audit-and-review to reduce unnecessary antibiotic use after discharge (Medium OCP). CP IV mines large administrative data sets and analyzes data from individual medical records to define the epidemiology of HOS, validate CDC's acute sepsis event algorithm for HOS, and identify remediable HOS risk factors that could be targets for preventive measures. The Large OCP will conduct a stepped wedge trial of a simple, inexpensive intervention—2 doses of intranasal povidone iodine—to prevent SSI in patients with high- energy lower extremity fractures, who are a high-risk population with few available preventive measures. The Small OCP seeks to improve antibiograms and, therefore, antibiotic use by including geospatial information in antibiograms. This information should provide clinicians with information more specific to their patients.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "9838", "attributes": { "award_id": "5I01BX005475-02", "title": "COVID19: SARS-CoV-2 and ACE2 interaction in hypertension", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-06-01", "end_date": "2023-05-31", "award_amount": null, "principal_investigator": { "id": 24159, "first_name": "ERIC D", "last_name": "LAZARTIGUES", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1705, "ror": "", "name": "SOUTHEAST LOUISIANA VETERANS HEALTH CARE", "address": "", "city": "", "state": "LA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1705, "ror": "", "name": "SOUTHEAST LOUISIANA VETERANS HEALTH CARE", "address": "", "city": "", "state": "LA", "zip": "", "country": "United States", "approved": true }, "abstract": "The current COVID-19 pandemic is one of the most disruptive events in human history, caused by the SARS- CoV-2 virus, member of the coronavirus family that uses angiotensin converting enzyme 2 (ACE2), a transmembrane carboxypeptidase identified as a member of the renin-angiotensin system (RAS) as an entry point to the cells. Clinical reports suggest that pre-existing conditions such as hypertension, diabetes and obesity predispose to COVID-19 mortality. Considering that these co-morbidities are highly prevalent in Veterans and active duty personnel, these populations are at high risk of infection by SARS-CoV-2. The role of the brain RAS in the maintenance of normal blood pressure (BP) and in the neuro-cardiovascular dysregulation leading to hypertension has been firmly established. In addition, anosmia (loss of smell) is an early symptom of COVID-19 suggesting the brain is a primary target for SARS-CoV-2 infection. For the treatment of hypertension, two of the most popular drug choices are ACE inhibitors (ACEI) and angiotensin-II (Ang-II) type 1 receptor (AT1R) blockers (ARB). None of these classes of drugs have a direct effect on ACE2 activity, but there is evidence indicating that they may alter long-term ACE2 expression levels and subcellular localization, suggesting that patients taking these medications may be subject to more severe infections with SARS-CoV-2. Thus, clear data on the relationship between ACE2 plasma membrane levels, SARS-CoV-2 and co-expression of other RAS members are required to promptly adapt the therapy in this subset of patients. Beyond establishing ACE2 as a critical player in the prevention of neurogenic hypertension, our group was the first to report that Ang-II mediates ACE2 internalization and degradation via AT1R activation. Thus, the hypothesis of this proposal is that ACE2-AT1R complexes enhance SARS-CoV-2 infection in hypertensive Veterans while RAS blockers prevent ACE2 internalization and coronavirus infection. Taking advantage of unique resources, including a humanized transgenic mouse expressing human ACE2 constitutively, we will determine whether AT1R contribute to SARS- CoV-2 infection and whether ACEI and ARB reduce the incidence of COVID-19.", "keywords": [ "2019-nCoV", "ACE2", "Address", "Adult", "Affect", "Age", "Aldosterone", "American", "Angiotensin II Receptor", "Angiotensin-Converting Enzyme Inhibitors", "Angiotensins", "Anosmia", "Blood Pressure", "Brain", "Brain hemorrhage", "COVID-19", "COVID-19 mortality", "COVID-19 pandemic", "COVID-19 susceptibility", "Carboxypeptidase", "Cardiovascular system", "Cell Culture Techniques", "Cell membrane", "Cells", "Clinical", "Clinical Trials", "Complex", "Coronary heart disease", "Coronavirus", "Coronavirus Infections", "Coronavirus spike protein", "Data", "Diabetes Mellitus", "Down-Regulation", "Enzymes", "Epithelial Cells", "Event", "Experimental Models", "Exposure to", "Family", "Human", "Human Resources", "Hypertension", "In Vitro", "Incidence", "Individual", "Infection", "Inflammation", "Ischemia", "Knock-in Mouse", "Life Style", "Light", "Losartan", "Lung", "Lysosomes", "Maintenance", "Mediating", "Medical", "Molecular", "Mus", "Neurons", "Obesity", "Patients", "Peptides", "Peptidyl-Dipeptidase A", "Pharmaceutical Preparations", "Pharmacology", "Population", "Predisposition", "Prevention", "Public Health", "Receptor Activation", "Receptor Angiotensin Type 1", "Recording of previous events", "Renin-Angiotensin System", "Reporting", "Resources", "Risk Factors", "Role", "SARS-CoV-2 infection", "Sodium Chloride", "Symptoms", "System", "Telemetry", "Testing", "Therapeutic", "Time", "Transgenic Mice", "Ubiquitination", "Up-Regulation", "Vasodilator Agents", "Vasopressins", "Veterans", "Viral", "Virus", "Virus Diseases", "Water", "active duty", "angiotensin I (1-7)", "base", "comorbidity", "diabetic patient", "high risk", "hypertension treatment", "hypertensive", "improved", "in vivo", "infection rate", "inhibitor", "member", "mouse model", "neurogenic hypertension", "novel therapeutic intervention", "obese patients", "overexpression", "patient subsets", "preservation", "prevent", "receptor", "therapeutic evaluation", "tool", "vascular bed", "vasoconstriction" ], "approved": true } }, { "type": "Grant", "id": "9846", "attributes": { "award_id": "5I01HX003221-02", "title": "Addressing insufficient positive airway pressure use among older Veterans with obstructive sleep apnea", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-07-01", "end_date": "2025-09-30", "award_amount": null, "principal_investigator": { "id": 24186, "first_name": "Cathy A", "last_name": "Alessi", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [ { "id": 1708, "ror": "https://ror.org/05xcarb80", "name": "VA Greater Los Angeles Healthcare System", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1708, "ror": "https://ror.org/05xcarb80", "name": "VA Greater Los Angeles Healthcare System", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Background: The most frequently diagnosed sleep disorder among older Veterans is obstructive sleep apnea (OSA), which is associated with serious adverse effects on health, quality of life and survival. Positive airway pressure (PAP) is recommended as first-line treatment (particularly for moderate to severe OSA), but sustained use is difficult to achieve, including among older Veterans, and nearly half of patients with OSA who begin PAP therapy discontinue use within a year. Significance/Impact: Although OSA is a chronic condition, research to date has primarily focused on increasing initial PAP use in patients with newly diagnosed OSA. In addition, most research has not addressed PAP use in older adults, which is unfortunate given the high prevalence and important adverse effects of OSA on their health and well-being. Prior work suggests that behavioral interventions are effective in improving initial PAP use, but little is known of how to address insufficient use over time. Innovation: To address this problem, we developed and pilot-tested a structured, manual-based approach to address insufficient PAP use among older adults with previously diagnosed OSA. The intervention (5 sessions over 8 weeks, then monthly contact for up to 6 months) is designed so it can be provided by individuals (“sleep coaches”) from various disciplines (supervised remotely by a psychologist) in a variety of settings for maximal implementation. Core components of the intervention include: 1) educational and behavioral approaches to improve PAP use, 2) individualized self-management and troubleshooting techniques to address factors contributing to insufficient PAP use, and 3) ongoing review of objective PAP use (via remote monitoring). Specific Aims: Primary Aim 1 will test the efficacy of this intervention for improving PAP usage among older Veterans with previously diagnosed OSA who have insufficient PAP use. Our hypotheses are that the intervention will increase objectively measured PAP use at 6-months follow-up, with effects sustained at 12 months. Secondary Aim 2 will test for effects on sleep quality, daytime sleepiness and sleep-related function; and Exploratory Aim 3 will test for effects on health-related quality of life. Our hypotheses are that these outcomes will also improve at 6 months, and effects will be sustained at 12 months. Methodology: We propose a randomized, controlled trial to test this new intervention in older Veterans (aged > 65 years, N=90) with previously diagnosed OSA (moderate to severe) who were prescribed PAP 1-5 years in the past, but have insufficient PAP use (defined as no PAP use over the prior 30 days). Given prior growing interest in telehealth and remote monitoring approaches to optimize PAP use, and the ongoing COVID-19 pandemic, all aspects of the study will be performed virtually in keeping with the latest VA COVID-era guidance for the remote testing and treatment of OSA. Participants will be randomized to the intervention or a control program that mirrors “optimal usual care” for OSA plus general sleep education (attention control). Structured assessments at baseline, post-treatment (after session 5) and 6- and 12-months follow-up include objectively measured PAP use (via remote telemonitoring), sleep quality (Pittsburgh Sleep Quality Index), daytime sleepiness (Epworth Sleepiness Scale), sleep-related function (Functional Outcomes of Sleep-10) and health- related quality of life (PROMIS-29 v2.1 Physical and Mental Health Summary Scores). We will collect participant experiences and attitudes related to the intervention, and implementation outcome measures (acceptability, appropriateness, fidelity and staff time as an estimate of cost) to inform future implementation. Implementation/Next Steps: The long-term goal of this work is to effectively address insufficient PAP use among older Veterans with OSA to improve their health and quality of life. If successful, we will implement the intervention at our institution, and develop and disseminate an implementation package with actual tools needed to promote wider implementation of this model of care into clinical practice.", "keywords": [ "Address", "Adverse effects", "Aftercare", "Area", "Attitude", "Behavior Therapy", "Behavioral", "COVID-19 pandemic", "Cardiovascular Diseases", "Caring", "Chronic", "Clinical", "Data", "Diabetes Mellitus", "Diagnosis", "Discipline", "Disease", "Drowsiness", "Education", "Elderly", "Equipment", "Goals", "Health", "Healthcare Systems", "High Prevalence", "Hour", "Hypertension", "Hypoxia", "Impaired cognition", "Individual", "Information Systems", "Institution", "Intervention", "Left", "Manuals", "Measurement", "Measures", "Mental Depression", "Mental Health", "Methodology", "Modeling", "Newly Diagnosed", "Obstructive Sleep Apnea", "Outcome", "Outcome Measure", "Participant", "Patient Outcomes Assessments", "Patients", "Personal Satisfaction", "Pittsburgh Sleep Quality Index", "Prevalence", "Provider", "Psychologist", "Quality of life", "Randomized", "Randomized Controlled Trials", "Reporting", "Research", "Risk", "Self Management", "Services", "Sleep", "Sleep Apnea Syndromes", "Sleep Disorders", "Structure", "Supervision", "Techniques", "Telephone", "Testing", "Time", "Treatment Efficacy", "Veterans", "Work", "adverse outcome", "aged", "airway obstruction", "attentional control", "base", "clinical practice", "coronavirus disease", "cost estimate", "design", "effective intervention", "efficacy testing", "experience", "follow-up", "functional outcomes", "future implementation", "health related quality of life", "implementation outcomes", "improved", "innovation", "interest", "novel", "novel strategies", "outreach", "physical conditioning", "pilot test", "positive airway pressure", "primary outcome", "programs", "remote grading", "remote health care", "remote monitoring", "remote therapy", "sleep quality", "stroke recovery", "telehealth", "telemonitoring", "tool", "treatment as usual", "virtual" ], "approved": true } }, { "type": "Grant", "id": "9852", "attributes": { "award_id": "5U60OH010908-08", "title": "Georgia Occupational Health Surveillance Program", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 22791, "first_name": "Linda", "last_name": "West", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-07-01", "end_date": "2026-06-30", "award_amount": 170000, "principal_investigator": { "id": 24192, "first_name": "A. Rana", "last_name": "Bayakly", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1498, "ror": "", "name": "GEORGIA STATE DEPARTMENTOF PUBLIC HEALTH", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1498, "ror": "", "name": "GEORGIA STATE DEPARTMENTOF PUBLIC HEALTH", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "The Georgia Department of Public Health Occupational Safety and Health Surveillance Program (GA-OHS) proposes to strengthen its current occupational safety and health surveillance and build upon its capacity by establishing a Fundamental-Plus Program. GA-OHS will continue to systematically collect, analyze, interpret, and disseminate data on the state employment profile and the 24 OHIs that have been recommended by the National Institute for Occupational Safety and Health (NIOSH) and the Council of State and Territorial Epidemiologists (CSTE). Additionally, the GA-BRFSS, will be analyzed annually to obtain data for two identified state- specific OHIs: workplace secondhand smoke exposure and arthritis among employees. Georgia Violent Death Reporting System (GA-VDRS) data will also be analyzed annually for a new state-specific indicator on work-related violent deaths to determine the magnitude of workplace and work-related homicides and suicides in Georgia. GA-OHS will conduct in-depth analyses and surveillance of OHIs with rates that have increased over time in Georgia, OHIs that have rates above the national average, and those identified as emerging issues. These priority OHIs and emerging conditions include work-related transportation incidents, work-related pesticide associated illness and injury, and work-related COVID-19. In collaboration with the DPH Environmental Health Section, GA-OHS will implement follow-back investigations of resident incident cases age 16 years and older with elevated BLLs of ≥ 25 µg/dL. GA-OHS proposes to maintain and build upon its current capacity to conduct Fundamental OH Surveillance by establishing two new in-depth surveillance activities (Fundamental-Plus projects). For Project One, GA-OHS will conduct in-depth assessment and follow-back activities for work-related and workplace suicides. Follow-back activities will be conducted with employers who would like to receive mental health trainings or resources available for their employees. For Project Two, GA-OHS will work in collaboration with the Georgia Council on Respiratory Health Promotion and DPH Asthma Control and Prevention Program to create a policy and intervention program for work-related asthma. GA-OHS will maintain an Advisory Committee including representatives of key partners and stakeholder organizations and agencies. We will also participate fully in CDC/NIOSH- and recipient-convened meetings or conference calls of grantees and collaborate with other state surveillance programs and key organizations on topics of mutual interest. GA-OHS will use results from data analyses and surveillance findings to inform the development of new partnerships and facilitate implementation of intervention and/or prevention activities. Expected project outputs and outcomes include, but are not limited to: • Occupational health surveillance reports, data summaries, and scientific journal articles • Increased awareness and development of resources for work-related transportation incidents, work-related pesticide injuries/illnesses, and work-related COVID-19 • Development and dissemination of lead exposure educational materials, guidance, and training resources for workers and employers to help reduce occupational lead exposures • Increased awareness of workplace and work-related suicides in Georgia • Development and dissemination of resources to increase mental health awareness in workplaces • Development and dissemination of work-related asthma educational materials for health care providers, employers, and workers • A policy for surveillance and intervention of work-related asthma.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "9863", "attributes": { "award_id": "5U01OH012272-02", "title": "Neuropsychological Profile and Neurocognitive Biomarkers of Attention and Memory in Trauma-Exposed Responders at Risk of Premature Cognitive Decline", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-07-01", "end_date": "2026-06-30", "award_amount": 599267, "principal_investigator": { "id": 24209, "first_name": "YAEL M", "last_name": "CYCOWICZ", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 812, "ror": "", "name": "NEW YORK STATE PSYCHIATRIC INSTITUTE", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 812, "ror": "", "name": "NEW YORK STATE PSYCHIATRIC INSTITUTE", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Direct trauma exposure is associated with negative physical and mental health consequences, including an increased risk of rapid decline of cognitive function, which may start early in midlife. Moreover, additional life traumas such as COVID-19, as well as chronic illnesses, have also been shown to accelerate cognitive aging. During the World Trade Center terror attack and its aftermath, tens of thousands of traditional first responders and other cleanup and recovery workers were exposed to the emotional trauma and to environmental toxicants, and they had high rates of subsequent physical and psychiatric disorders. The time to detect cognitive decline is before the onset of more obvious symptoms, so that the underlying neurodegeneration may be delayed or lessened. To evaluate the risk of cognitive decline, we will use remote web-based neuropsychological tasks to assess core cognitive functioning among the youngest first responders (N=1,200) in two waves, 40 months apart. The different levels of trauma exposure, and consequent physical and mental outcomes, which have been well documented, may imply different levels of premature cognitive decline risk among the responders which will be considered in our experimental design and analytical models. We plan to recruit first responders who received health services through the WTC Health Program, a majority of whom were police and non-traditional rescue, recovery and cleanup workers, and compare the risk of cognitive decline between these groups. In addition, a sub-group of responders and additional community controls (N=120) will participate in a neurocognitive study using EEG and MRI to elucidate the neurobiological mechanisms associate with premature cognitive decline. Specifically, we will include core cognitive tasks (attention and episodic memory) to determine the neuronal underpinnings of early cognitive changes and will obtain measures of brain morphology and connectivity. This study will generate scientifically robust information to guide clinical and public health actions focused on premature cognitive decline among the youngest responders. A better understanding of premature cognitive decline and of the most important pathways causing such decline has the potential to improve interventions that can reduce premature cognitive decline in this and other cohorts.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "9864", "attributes": { "award_id": "5U01DD001293-02", "title": "Component A: North Carolina - Advancing Developmental Research using SEED and SEED Follow-up data", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-07-01", "end_date": "2026-06-30", "award_amount": 588918, "principal_investigator": { "id": 24212, "first_name": "Julie L", "last_name": "Daniels", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 817, "ror": "", "name": "UNIV OF NORTH CAROLINA CHAPEL HILL", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 817, "ror": "", "name": "UNIV OF NORTH CAROLINA CHAPEL HILL", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "- SEED Follow-up Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder that impacts approximately 1.5% of children in the United States. Individuals with ASD experience deficits in social communication or restricted interests and repetitive behavior; but the severity and patterns vary greatly and convey lifelong impairment for some. It is unclear how the presentation of ASD changes from early childhood into adolescence or adulthood. The causes of ASD are also unknown, though substantial evidence supports the contribution of both genes and environmental factors. These gaps in knowledge exist because US studies to date have lacked the sample size, depth of data collection, or appropriate life course timing to address these questions. The Study to Explore Early Development (SEED) is now able to address these prior limitations. SEED is a large case- control study of children ages 2-5 years and their families, implemented across eight states over three phases. SEED collected detailed data on children’s core ASD symptoms, cognitive status, and presence of co- occurring conditions in early childhood, along with extensive risk factors related to maternal health and the perinatal environment as well as genomics. The SEED sample includes 2044 children with ASD, 1950 children with non-ASD developmental disabilities (DD), and 2285 population control children (POP), making this the largest etiologic study of ASD in the US. Recent ancillary studies - the SEED Teen Pilot and SEED COVID studies -- will soon add data on adolescent health and the consequences of the pandemic, respectively, for some SEED participants. The work proposed here, SEED Follow-up Studies (SEED FU), will maximize the impact of extant SEED data through analyses that characterize ASD phenotypes and assess the potential interplay between genetic and modifiable risk factors. SEED FU will also facilitate new data collection in middle childhood, adolescence and early adulthood to characterize changes in ASD phenotype across developmental stages, and the associated health, educational, and service needs across the early life course. These data will further enable prospective analyses of associations between early life factors and later childhood through early adulthood outcomes. Studying risk factors in relation to life course phenotypic subgroups may also help elucidate etiologies previously masked in ASD case-control studies. The NC SEED Team in combination with the SEED Network’s collaborative infrastructure and extensive extant data resources, will ensure the successful implementation of the SEED FU Study in North Carolina and contribute to success across the network. SEED is well-powered for making significant contributions to our understanding of the complex autism phenotype and identifying factors associated with ASD risk in the population. The knowledge gained by SEED FU will greatly advance our ability prevent adverse developmental outcomes and to support individuals with ASD and their families to ensure optimal wellbeing through early adulthood.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "9869", "attributes": { "award_id": "5U01DD001290-02", "title": "Colorado SEED Component A & Component B", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-07-01", "end_date": "2026-06-30", "award_amount": 730002, "principal_investigator": { "id": 24217, "first_name": "CAROLYN G", "last_name": "DIGUISEPPI", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 784, "ror": "https://ror.org/02hh7en24", "name": "University of Colorado Denver", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 784, "ror": "https://ror.org/02hh7en24", "name": "University of Colorado Denver", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder that impacts approximately 1.5% of children in the United States. Individuals with ASD experience deficits in social communication or restricted interests and repetitive behavior; but the severity and patterns vary greatly and convey lifelong impairment for some. It is unclear how the presentation of ASD changes from early childhood into adolescence or adulthood. The causes of ASD are also unknown, though substantial evidence supports the contribution of both genes and environmental factors. These gaps in knowledge exist because US studies to date have lacked the sample size, depth of data collection, or appropriate life course timing to address these questions. The Study to Explore Early Development (SEED) is now able to address these prior limitations. SEED is a large case- control study of children ages 2-5 years and their families, implemented across eight states over three phases. SEED collected detailed data on children's core ASD symptoms, cognitive status, and presence of co- occurring conditions in early childhood, along with extensive risk factors related to maternal health and the perinatal environment as well as genomics. The SEED sample includes 2044 children with ASD, 1950 children with non-ASD developmental disabilities (DD), and 2285 population control children (POP), making this the largest etiologic study of ASD in the US. Recent ancillary studies - the SEED Teen Pilot and SEED COVID studies -- will soon add data on adolescent health and the consequences of the pandemic, respectively, for some SEED participants. The work proposed here, SEED Follow-up Studies (SEED FU), will maximize the impact of extant SEED data through analyses that characterize ASD phenotypes and assess the potential interplay between genetic and modifiable risk factors. SEED FU will also facilitate new data collection in middle childhood, adolescence and early adulthood to characterize changes in ASD phenotype across developmental stages, and the associated health, educational, and service needs across the early life course. These data will further enable prospective analyses of associations between early life factors and later childhood through early adulthood outcomes. Studying risk factors in relation to life course phenotypic subgroups may also help elucidate etiologies previously masked in ASD case-control studies. The NC SEED Team in combination with the SEED Network's collaborative infrastructure and extensive extant data resources, will ensure the successful implementation of the SEED FU Study in North Carolina and contribute to success across the network. SEED is well-powered for making significant contributions to our understanding of the complex autism phenotype and identifying factors associated with ASD risk in the population. The knowledge gained by SEED FU will greatly advance our ability prevent adverse developmental outcomes and to support individuals with ASD and their families to ensure optimal wellbeing through early adulthood.", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1405, "pages": 1424, "count": 14236 } } }